ATG5 and acute myeloid leukemia: The results showed that the expression of MAP1LC3B, ATG5, ATG10, RB1CC1, and AMBRA1 genes was significantly downregulated in CR patients as compared to newly diagnosed AML patients (0.71, 0.73, 0.5, 0.72, and 0.75 folds, respectively) (p = 0.006, 0.003, 0.0002, 0.006, and 0.004, respectively).